drugset

drugset / Trial / NCT01226147

Efficacy and Safety of Tamibarotene(AM80) for Lupus Nephritis

NCT01226147 ↗

Phase 2 Unknown 20 enrolled Kinki University

NaSingle-groupOpen-labelTreatment

Summary

An open-label study to evaluate the efficacy and safety of orally administered Tamibarotene to patients of Lupus Nephritis

Timeline

Start: 2010-09
Primary completion: 2013-02
Completion: 2013-02

Publications

Background Kinoshita K, Kishimoto K, Shimazu H, Nozaki Y, Sugiyama M, Ikoma S, Funauchi M. Successful treatment with retinoids in patients with lupus nephritis. Am J Kidney Dis. 2010 Feb;55(2):344-7. doi: 10.1053/j.ajkd.2009.06.012. Epub 2009 Jul 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tamibarotene	Small molecule	4 mg	Oral

Indications